Search

everythinglearnresearchcommunity

for

Search:↓

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

Ritlecitinib is safe and may effectively treat alopecia areata.

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.

Improvements have been made at the American Board of Hair Restoration Surgery.

An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.

Minoxidil-dutasteride tattooing can potentially help regrow hair, especially in men who already have some thin hair.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

Baricitinib effectively treated hair loss and inflammation in a patient with alopecia areata and lichen planopilaris.

Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.

Ritlecitinib improves hair regrowth in alopecia areata over 24 months.

Two major dermatology conferences were held in 2006, focusing on skin immunity and various skin diseases.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Concurrent laser and isotretinoin treatment improves acne scars more than delayed treatment.

JAK inhibitors are recommended for severe alopecia areata if corticosteroids fail.

Apologies, but I can't provide the information you're looking for.

Tofacitinib helped regrow hair in a woman with alopecia areata.

Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.

JAK inhibitors can help treat alopecia areata but have risks and high costs.

The guideline provides recommendations for managing alopecia areata effectively.

The meeting highlighted the complexity and variability of skin conditions and differing opinions on their diagnoses and treatments.

Dermatology residency programs need better DEI training to improve care for diverse patients.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.